19-hydroxyandrostenedione does not modulate [3H]aldosterone binding to human mononuclear leucocytes and rat renal cytosol-Reference-Cited by-同舟云学术

19-hydroxyandrostenedione does not modulate [3H]aldosterone binding to human mononuclear leucocytes and rat renal cytosol

Published:1991-03 Issue:3 Volume:38 Page:331-337
ISSN:0960-0760
Container-title:The Journal of Steroid Biochemistry and Molecular Biology
language:en
Short-container-title:The Journal of Steroid Biochemistry and Molecular Biology

Author:

Murase Hiroshi,Yasuda Keigo,Mercado-Asis Leilani B.,Mori Akihiro,Shimada Takeshi,Mune Tomoatsu,Morita Hiroyuki,Noritake Nobuyasu,Yamakita Noriyoshi,Miura Kiyoshi

Publisher

Elsevier BV

Subject

Cell Biology,Clinical Biochemistry,Endocrinology,Molecular Biology,Molecular Medicine,Biochemistry,Endocrinology, Diabetes and Metabolism

Reference17 articles.

1. Amplification of the action of subthreshold doses of aldosterone by 19-hydroxyandrost-4-ene-3,17-dione;Sekihara;Biochem. Biophys. Res. Commun.,1979

2. 19-hydroxyandrostenedione: a potent hypertensinogenic steroid in man;Sekihara;J. Steroid Biochem.,1983

3. 19-hydroxyandrostenedione- a factor in pregnancy hypertension;Martin;Clin. Exp. Hyper.,1985

4. A comparative study of C19 steroid-induced hypertension and deoxycorticosterone acetate(DOCA)-salt hypertension;Manabe;Folia Endocr. (Jap.),1984

5. A reevaluation of the mineralocorticoid and hypertensinogenic potential of 19-hydroxyandrostenedione;Gomez-Sanchez;Endocrinology,1986

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SM-368229, a Novel Selective and Potent Non-steroidal Mineralocorticoid Receptor Antagonist With Strong Urinary Na+ Excretion Activity;Journal of Pharmacological Sciences;2011

2. 19-Hydroxyandrostenedione amplifies the hypertensive action of mineralocorticoids in rats;Journal of Endocrinology;1993-07

3. Aldosterone binding to mineralocorticoid receptors of mononuclear leukocytes in diabetic subjects;Acta Endocrinologica;1993-06

4. Overview: Novel Analogues of Mineralocorticoids, Antimineralocorticoids and Related Compounds;Current Opinion on Therapeutic Patents;1991-12